Paladin mounts hostile bid for Afexa

Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences, which makes the flu drug COLD-FX. In a deal that values the company at $56.7 million, Paladin has bid 55 cents a share for the 85% of the company it doesn't already own. Report